Prognosis in UC After First Biological

Completed

• Conditions: Ulcerative Colitis

• Registration Number: NCT05530122
• Lead Sponsor: Tampere University Hospital

Brief Summary

To study the long-term clinical outcome of patients with ulcerative colitis treated with first trial of biological therapy.

Detailed Description

UC patients treated with at least one biological in Tampere University Hospital between January 2009 and January 2020 were identified and reviewed from patient records.

Study Timeline

• Study Start: 2009-01
• Primary Completion: 2020-01
• Study Completion: 2022-08-26
• Study First Submitted: 2022-08-29
• Status Verified: 2022-09
• Study First Submitted QC: 2022-09-02
• Last Update Submitted: 2022-09-02
• Study First Posted: 2022-09-07
• Last Update Posted: 2022-09-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 192

Inclusion Criteria

• Patients treated for ulcerative colitis for the first trial of biological

Exclusion Criteria

• Age under 16 years

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Side-effects	within 5 years	treatment related side-effects reported
Response to treatment	within 5 years	Need for colectomy or enhancement of treatment within follow-up